Tarsus Pharmaceuticals (TARS) Earnings Analysis

Tarsus Pharmaceuticals (TARS) next reports earnings on 2026-08-06, consensus EPS -0.21 USD. Last quarter (2026-02-23) it missed with EPS -0.2 USD vs -0.103 USD est (-94.2%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -50.51.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TARS next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.21 USD
Revenue estimate0.17B

TARS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-23-0.2 USD-0.103 USD-94.2%Miss
2025-05-01-0.64 USD-0.69 USD+7.2%Beat

Beat rate: 1/2 (50%) over reported quarters with consensus data.

TARS valuation and analyst view

Trailing P/E-50.51
Trailing EPS-1.12357 USD
Price / book7.09
Dividend yield0.00%
Market cap2.48B
Analyst consensusBuy (8 buy / 1 hold / 0 sell)
Avg price target89 USD

Related research pages

Frequently asked questions

When is Tarsus Pharmaceuticals (TARS)'s next earnings date?

Tarsus Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.21 USD and revenue estimate of 0.17B.

Did TARS beat earnings last quarter?

In its 2026-02-23 report, TARS posted EPS of -0.2 USD versus a -0.103 USD estimate — a miss of 94.2%.

What is TARS's earnings track record?

Over the last 2 reported quarters with consensus data, TARS beat estimates 1 times (50%).

What is TARS's current P/E ratio and EPS?

TARS trades at a trailing P/E of -50.51 on trailing EPS of -1.1235661320922217 USD.

What do analysts rate TARS?

Analyst consensus is "Buy" across 9 ratings (1 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 89 USD.